NanoVibronix
ELMSFORD, New York, United States · Biotechnology, Health Care, Manufacturing
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Tyler, Texas, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications
Key facts
- Headquarters
- ELMSFORD, New York, United States
- Employees
- 13
- Industries
- Biotechnology, Health Care, Manufacturing
- Status
- Public (FEED)
- Website
- nanovibronix.com
- Company page
Recent activity at NanoVibronix
- : SEC 8-K (1.01):
- : SEC 8-K (8.01): On August 28, 2026, ENvue Medical, Inc. announced a 1-for-12 reverse stock split through a press release. This action required an amendment to the company's Certificate of Incorporation, as detailed in Exhibit 3.1. The reverse stock split implies a reduction in the number of shares and could impact shareholder value and stock price dynamics. The strategic intent behind this move may be to improve share marketability or compliance with exchange listing requirements.
- : SEC 8-K (1.01): On August 12, 2026, ENvue Medical, Inc. entered into a Common Shares Purchase Agreement with an institutional investor for a committed equity facility of up to $50 million. The Agreement allows the Company to sell its common stock to the Investor based on market conditions and company discretion. 40% of the net proceeds from these sales are to be used to redeem outstanding Series X Preferred Stock, and the remainder will be allocated for working capital. The Investor's obligation to purchase shares is contingent upon the effective registration statement with the SEC.
- : SEC 8-K (5.02): On July 14, 2026, David Johnson and Nino Pionati voluntarily resigned from their positions as members of the Board of Directors of ENvue Medical, Inc. Their resignations were not a result of any disagreements with the Company. The Board appointed Zvi Joseph and Lior Buchman to fill the resulting vacancies; Mr. Joseph will serve on the Audit Committee and Nominating and Corporate Governance Committee, while Mr. Buchman will sit on the Audit Committee and Compensation Committee, and become the Chairman of the Compensation Committee. Additionally, Zeev Rotstein was appointed Chair of the Nominating and Corporate Governance Committee and as the new Chairman of the Board. The newly appointed directors will receive remuneration equivalent to that of other non-executive directors of the Company.
- : SEC 8-K (5.02): On February 2, 2026, ENvue Medical, Inc. amended the Amended and Restated Employment Agreement with Doron Besser, M.D. (the 'Besser Employment Agreement'). The amendment stipulates that Dr. Besser will receive an Initial Grant of 180,000 restricted stock units, representing 9% of the company's common stock, no later than 60 days following the effective date of December 17, 2025. Additionally, if terminated without cause or resigns for good reason, he will receive a prorated Gross-Up of stock units. In a separate agreement on the same day, David Johnson was appointed as the Chairman of the Board with a set compensation package. This move aligns with the company's strategy to bolster its leadership team and maintain key equity interests within its executive ranks.
- : SEC 8-K (1.01): On January 30, 2026, ENvue Medical, Inc. entered into an Amendment Agreement with the Required Holders to modify the terms of the Series H Convertible Preferred Stock. This amendment involved filing a Certificate of Amendment to remove the Floor Price, allowing the holders to exercise $2,500,000 of their Additional Investment Right. The amended Certificate of Designations became effective upon filing with the Secretary of State of Delaware. This strategic move aims to enhance the investment conditions for existing shareholders.
- : SEC 8-K (5.02):
- : SEC 8-K (5.02):
- : SEC 8-K (7.01): On December 12, 2025, Envue Medical, Inc. announced a Name Change and Symbol Change through a press release. This change reflects a new branding strategy intended to enhance the company's market visibility and alignment with its long-term goals. The press release is furnished as Exhibit 99.1 and marks a significant step in the company's rebranding efforts. There are no specific financial amounts mentioned, but the change is expected to have strategic implications for investor perception and engagement in the market.
- : SEC 8-K (5.02):
NanoVibronix funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2023 | Venture | $13.5M |
| Dec 2020 | Venture | $6.6M |
| Jul 2020 | Seed | $450K |
| Apr 2017 | Venture | $250K |
| Apr 2017 | Pre-Seed | $100K |
Leadership
- Brian Murphy, Executive Officer, Director
- Christopher Fashek, Director
- Harold Jacob, Executive Officer, Director
- Michael Ferguson, Director
- Mika Thomas, Director
- Martin Goldstein, Director
- Aurora Cassirer, Director
- Maria Schroeder, Director
- Brian Murphy, Executive Officer, Director
- Harold Jacob, Executive Officer, Director
- Christopher Fashek, Director
- Martin Goldstein, Director
Verified email and direct lines for NanoVibronix’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
NanoVibronix in the news
- ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities - Yahoo Finance (Aug 04, 2026)
- NanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus - BioSpace (Aug 23, 2023)
- NanoVibronix, Inc. Announces Name and Ticker Symbol Change to ENvue Medical, Inc. and ‘FEED’ - Yahoo Finance (Dec 12, 2025)
- Nanovibronix (FEED) Stock Price, News & Analysis $FEED - MarketBeat (Jan 29, 2026)
- ENvue Medical Resumes U.S. Commercial Shipments of - GlobeNewswire (Sep 09, 2026)
- NanoVibronix to Launch Rental Program for PainShield and UroShield - BioSpace (Feb 22, 2023)
- NanoVibronix Inc. (NAOV) Share Price Today | NanoVibronix (NAOV) Live NSE/BSE - Value Research (May 30, 2022)
- ENvue Medical Launches AI Training Platform Establishing - GlobeNewswire (Jun 09, 2026)
Companies similar to NanoVibronix
- SpineCorporation · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Planatome · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- PanTera · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- Colospan Ltd · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
- FesariusTherapeutics · Biotechnology, Health Care, Manufacturing, Medical, Medical Device
About NanoVibronix: questions and answers
What does NanoVibronix do?
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Tyler, Texas, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications
Where is NanoVibronix headquartered?
NanoVibronix is headquartered in ELMSFORD, New York, United States.
How many employees does NanoVibronix have?
NanoVibronix has about 13 employees.
Has NanoVibronix raised funding?
Yes. Fundz has recorded 5 funding events for NanoVibronix. The most recent, $13.5M, was in Sep 2023.
What is the latest news on NanoVibronix?
On Oct 08, 2026, SEC 8-K (1.01):
Is NanoVibronix a public company?
Yes. NanoVibronix is publicly traded under the ticker FEED.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy